FOR IMMEDIATE RELEASE
November 15, 2014
MIAMI, FLORIDA: Five studies presented at the 19th Annual Scientific Meeting of the Society for Neuro-Oncology (SNO) were highlighted today in a special briefing for members of the press. Presentations focused on new studies exploring the development of new therapies and drugs for treating brain tumors. The SNO Meeting takes place November 13-16, 2014, at the Loews South Beach Hotel in Miami, Florida.
The studies highlighted were:
- NT-40 Interim analysis of the EF-14 trial: A prospective, multi-center trial of NovoTTF-100A together with temozolomide compared to temozolomide alone in patients with newly diagnosed GBM
Stupp R, Wong ET, Scott CB, Kirson ED, Palti Y, Taillibert S, Kanner A, Easaw JC, Barnett GH, Kesari S, Sroubek J, Nam D, Toms SA, Silvani A, Ram Z
- AT-55 Final analysis of the BELOB trial (A randomized phase II study on bevacizumab versus bevacizumab plus lomustine versus lomustine single agent in recurrent glioblastoma) and first radiology review results
Taal W, Enting R, Taphoorn M, Smits M, Dubbink H, Beerepoot L, Hanse M, Bralten L, Oosterkamp H, Walenkamp A, Buter J, Honkoop A, Boerman D, de Vos F, Bromberg J, Vernhout R, van der Holt B, van den Bent M
- AT-13 R9802: Phase III study of radiation therapy (RT) with or without procarbazine, CCNU, and vincristine (PCV) in low-grade qlioma: Results by histologic type
Buckner J, Shaw E, Pugh S, Gilbert M, Barger G, Coons S, Ricci P, Bullard D, Brown P, Stelzer K, Brachman D, Suh J, Schultz C, Bahary J-P, Fisher B, Kim H, Murtha A, Won M, Mehta M, Curran Jr W
- GE-41 Comprehensive and integrative genomic characterization of diffuse lower grade gliomas
Yung WKA, Verhaak R, Cooper L, Salama S, Aldape K, Brat D
- IT-30 ReACT: A phase II study of rindopepimut vaccine (CDX-110) plus bevacizumab in relapsed glioblastoma
Reardon D, Schuster J, Tran D, Fink K, Nabors L, Li G, Lukas R, Desjardins A, Ashby L, Duic JP, Aneiro L, Hawthorne T, Green J, Yellin M, Davis T, Sampson J
Of note, results from the study EF-14, regarding an interim analysis of a novel treatment modality that inhibits the growth of cancer cells through rapidly changing electric fields, so called Tumor Treating Fields (TTFields), were particularly encouraging. “These interim data are very exciting and demonstrate a strong survival benefit associated with the NovoTTF-100A device, based on results from a well-controlled randomized clinical trial” said David Reardon, MD, President of SNO and Clinical Director of the Center for Neuro-Oncology the Dana-Farber Cancer Institute. Dr. Reardon went on to add that "These interim data are very exciting and demonstrate a strong survival benefit associated with the NovoTTF-100A device, based on results from a well-controlled randomized clinical trial” said David Reardon, MD, President of SNO and Clinical Director of the Center for Neuro-Oncology the Dana-Farber Cancer Institute. Dr. Reardon went on to add that "NovoTTF-100A is a novel therapy that offers new hope for GBM patients".
With regard to ReACT vaccine study, Dr. Patrick Wen, Scientific Co-Chair of the 2014 Society for Neuro-Oncology Annual Meeting and Director of the Center for Neuro-Oncology at the Dana-Farber Cancer Institute remarked, “The interim results of this well-controlled, randomized phase II study demonstrate a strong survival benefit associated with Rindopepimut, among recurrent glioblastoma patients. This group of patients has historically been very challenging to treat. Furthermore patients who generated antibody responses following the vaccine did particularly well suggesting that such responses could be a potential biomarker to identify patients most likely to benefit long-term.”
Founded in 1995, the Society for Neuro-Oncology (SNO) is the world’s leading professional organization representing physicians and scientists involved in the study and treatment of tumors of the central nervous system. With nearly 2,000 members from over 40 countries, SNO is committed to improving brain tumor care through scientific meetings, educational programs and two peer-reviewed journals published by Oxford University Press. For more information about SNO, visit www.soc-neuro-onc.org.